Enliven Therapeutics, Inc. (ELVN)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Enliven Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 46.19 | 49.66 | 44.55 | 49.43 | 969,794 |
| Nov 5, 2026 | 47.10 | 47.73 | 44.60 | 44.79 | 1,585,854 |
| Nov 4, 2026 | 45.74 | 47.31 | 44.21 | 47.25 | 2,707,283 |
| Nov 3, 2026 | 45.25 | 45.90 | 44.63 | 44.83 | 2,125,586 |
| Nov 2, 2026 | 44.48 | 45.06 | 43.23 | 44.63 | 1,138,652 |
| Oct 30, 2026 | 44.92 | 45.87 | 44.09 | 44.25 | 1,236,955 |
| Oct 29, 2026 | 45.29 | 45.72 | 44.44 | 45.08 | 909,464 |
| Oct 28, 2026 | 43.69 | 44.94 | 43.39 | 44.78 | 1,261,399 |
| Oct 27, 2026 | 41.80 | 44.37 | 41.52 | 43.69 | 3,308,456 |
| Oct 26, 2026 | 41.58 | 42.17 | 40.90 | 41.49 | 2,323,118 |
| Oct 23, 2026 | 41.49 | 41.64 | 40.82 | 41.52 | 2,298,505 |
| Oct 22, 2026 | 41.55 | 42.87 | 41.06 | 41.93 | 2,324,856 |
| Oct 21, 2026 | 41.76 | 42.92 | 41.59 | 41.82 | 2,052,547 |
| Oct 20, 2026 | 38.86 | 41.37 | 38.41 | 41.25 | 1,938,238 |
| Oct 19, 2026 | 38.01 | 38.83 | 37.50 | 38.70 | 1,312,315 |
| Oct 16, 2026 | 39.33 | 39.47 | 36.95 | 37.32 | 1,188,446 |
| Oct 15, 2026 | 39.48 | 40.29 | 38.49 | 39.33 | 2,053,739 |
| Oct 14, 2026 | 38.99 | 39.95 | 38.51 | 39.28 | 1,217,094 |
| Oct 13, 2026 | 40.56 | 40.99 | 39.27 | 39.49 | 847,875 |
| Oct 12, 2026 | 40.67 | 41.41 | 40.50 | 40.84 | 579,824 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Kunkel Lori Anne | Director | Option Exercise | 3.7K | -- | Oct 30, 2026 |
| Kunkel Lori Anne | Director | Option Exercise | 7.3K | -- | Oct 30, 2026 |
| Kunkel Lori Anne | Director | Option Exercise | 3.7K | $4.2K | Oct 30, 2026 |
| Kunkel Lori Anne | Director | Option Exercise | 7.3K | $133.6K | Oct 30, 2026 |
 Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sale | 6.0K | $231.5K | Oct 19, 2026 |
 Collins Helen Louise | CHIEF MEDICAL OFFICER | Option Exercise | 5.0K | -- | Oct 19, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
FMR LLC · also on 13F· joint filing· may incl. warrants· filed Aug 2026 | 10.7M | 14.6% | 13G |
FMR LLC | 10.0M | 13.6% | 13F |
ORBIMED ADVISORS LLC | 6.8M | 9.2% | 13F |
ORBIMED ADVISORS LLC · also on 13F· joint filing· may incl. warrants· filed Jun 2026 | 6.8M | 9.2% | 13D |
Polar Capital Holdings Plc | 6.4M | 8.7% | 13F |
BlackRock, Inc. · net of 13F· may incl. warrants· filed Oct 2026 | 5.2M | 7.1% | 13G |
Polar Capital Holdings Plc · also on 13F· joint filing· may incl. warrants· filed Jun 2026 | 5.1M | 6.9% | 13G |
Commodore Capital LP · also on 13F· joint filing· filed May 2026 | 3.3M+1.5M via warrants | 6.5% | 13G |
BlackRock, Inc. | 4.4M | 5.9% | 13F |
Vestal Point Capital, LP | 4.0M | 5.4% | 13F |
Insiders
- Kunkel Lori AnneDirector
- Hohl BenjaminCHIEF FINANCIAL OFFICER
- Collins Helen LouiseCHIEF MEDICAL OFFICER
- BALL KRISTINE MDirector
- Garland J. ScottDirector
- Derynck Mika KDirector
- ORBIMED ADVISORS LLC10% Owner
- Heyman Richard A.Director
- Ballal Rahul D.Director
- Patel AnishCHIEF OPERATING OFFICER
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer.
Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene.
The company's base of operations is located in Boulder, Colorado.
13F filers report 81.99M shares, more than the 73.60M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.
US30d Avg
1.67M
60d Avg
1.62M
90d Avg
1.36M